Key Pipeline Biosimilars
| Reference Biologic | Annual Cost | Expected Biosimilar Launch | Potential Savings |
|---|---|---|---|
| Stelara (ustekinumab) | $80,000–$120,000 | 2025–2026 | 30–50% |
| Dupixent (dupilumab) | $40,000–$60,000 | 2027–2028 | 30–40% |
| Keytruda (pembrolizumab) | $150,000–$200,000 | 2028–2030 | 30–40% |
| Opdivo (nivolumab) | $150,000–$200,000 | 2028–2030 | 30–40% |
Formulary Planning
Preparing for biosimilar launches requires proactive formulary planning. When a biosimilar launches, the employer should: (1) add the biosimilar to the formulary at a preferred tier; (2) move the reference biologic to a non-preferred tier; (3) implement step therapy requiring biosimilar trial for new starts; and (4) develop a non-medical switching program for stable patients.
Pipeline Monitoring
Pro Tip
Monitor the biosimilar pipeline to prepare for upcoming launches. The FDA's biosimilar approval tracker and the Biosimilars Council provide up-to-date information on biosimilar approvals and launches. Proactive formulary planning — before the biosimilar launches — ensures the employer captures savings immediately upon launch.